Nuvalent Inc (NUVL) vs ARS Pharmaceuticals, Inc. (SPRY)
The same free fields, in the same order, for both companies, so a figure on one line can be read straight across.
This page states measurements and nothing else. It does not rank the two companies, name one of them, or draw a conclusion from the figures.
Data as of Oct 27, 2026, for both companies.
The figures, field by field
A dash means the snapshot carries no figure for that company on that line. A line is dropped only when neither company has it, so a dash beside a figure is a fact about coverage, not about either company.
| NUVL | SPRY | |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
| Size band | MID | SMALL |
| Listing | Nasdaq GM | Nasdaq GM |
| Country | United States | United States |
| Theme | oncology | rare-disease |
| Price and returns | ||
| Last close | $123.96 | $3.92 |
| Return · 1 week | 0.00% | −7.33% |
| Return · 1 month | 0.00% | −5.08% |
| Return · 3 months | 0.00% | −30.86% |
| Return · year to date | +22.93% | −65.88% |
| Return · 1 year | +26.87% | −59.00% |
| Distance from the 52-week highThe last close measured against the highest close of the past 52 weeks. | −0.02% | −70.19% |
| 52-week high | $123.99 | $13.15 |
| 52-week low | $87.30 | $3.81 |
| Size and turnover | ||
| Market value · USDConverted to US dollars, so two companies listed in different currencies sit under one heading. | $9.79B | $389.83M |
| Turnover · median day, USDThe median value traded in a session over the past 50 sessions. | $149.69M | $5.31M |
| Employees | 234 | 195 |
| Valuation | ||
| Price to earnings · trailing | n/a (negative earnings) | n/a (negative earnings) |
| Price to earnings · forward | n/a (negative forward earnings) | n/a (negative forward earnings) |
| Price to sales | — | 3.42× |
| Price to book | 8.33× | 31.90× |
| Enterprise value to EBITDA | — | n/a (negative EBITDA) |
| Enterprise value to revenue | — | 3.66× |
| Earnings per share · trailing | -6.06 | -2.18 |
| Profitability | ||
| Gross margin | — | 71.37% |
| Operating margin | 0.00% | −182.62% |
| Profit margin | — | −184.24% |
| Return on equity | −41.19% | −210.35% |
| Return on assets | −22.51% | −48.02% |
| Growth | ||
| Revenue growth | — | +114.20% |
| Balance sheet and payout | ||
| Debt / equity (%) | — | 1,371.51 |
| Current ratio | 16.14 | 3.48 |
| Dividend yield | — | 0.00% |
| Payout ratio | 0.00% | 0.00% |
| Trend and volatility | ||
| RSI · 14 | — | 41.39 |
| ADX · 14 | — | 21.55 |
| 50-day average | — | $4.81 |
| 200-day average | — | $7.59 |
| Average true range · share of priceAverage true range over 14 sessions, stated as a share of the last close, so it can be read across two share prices. | — | 6.55% |
The full NUVL analysis
Everything this table leaves out for Nuvalent Inc: the plain-language summary and key points, the accumulation read, signal history, full fundamentals, market context, and the case each side of the NUVL argument makes.
$9.90 per stock, one time, 30 days of access.
Open the full NUVL analysisThe full SPRY analysis
Everything this table leaves out for ARS Pharmaceuticals, Inc.: the plain-language summary and key points, the accumulation read, signal history, full fundamentals, market context, and the case each side of the SPRY argument makes.
$9.90 per stock, one time, 30 days of access.
Open the full SPRY analysis